Role of Janus Kinase Inhibitors in the Treatment of Alopecia Areata

    July 2018 in “ Drug design, development and therapy ”
    Korn Triyangkulsri, Poonkiat Suchonwanit
    Studysummary This review summarizes existing evidence on the efficacy and safety of JAK inhibitors for treating alopecia areata and emphasizes the need for improved topical formulations.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on dovepress.com →
    Discuss this study in the Community →

    Research cited in this study 39

    1. An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis Journal of Investigative Dermatology · 2018
    2. Tofacitinib 2% Ointment, a Topical Janus Kinase Inhibitor, for the Treatment of Alopecia Areata: A Pilot Study of 10 Patients Journal of the American Academy of Dermatology · 2017
    3. Oral Tofacitinib Monotherapy in Korean Patients with Refractory Moderate-to-Severe Alopecia Areata: A Case Series Journal of the American Academy of Dermatology · 2017
    4. Complete Regrowth of Beard Hair with Ruxolitinib in an Alopecia Universalis Patient Skin appendage disorders · 2017
    5. Efficacy of Topical Tofacitinib in Promoting Hair Growth in Non-Scarring Alopecia: Possible Mechanism via VEGF Induction Archives of Dermatological Research · 2017
    6. Brazilian Experience of Treating Alopecia Universalis with Novel Antirheumatic Therapy Tofacitinib: A Case Series Rheumatology and Therapy · 2017
    7. Ruxolitinib Found to Cause Eyelash Growth: A Case Report Journal of medical case reports · 2017
    8. A Case of Topical Ruxolitinib Treatment Failure in Alopecia Areata Journal of cutaneous medicine and surgery · 2017
    9. Topical Janus Kinase Inhibitors for the Treatment of Pediatric Alopecia Areata Journal of the American Academy of Dermatology · 2017
    10. Successful Hair Regrowth in a Korean Patient with Alopecia Universalis Following Tofacitinib Treatment Singapore Medical Journal · 2017
    11. Treatment of Alopecia Areata With Tofacitinib JAMA Dermatology · 2017
    12. Two Cases of Alopecia Areata Treated with Ruxolitinib: A Discussion of Ideal Dosing and Laboratory Monitoring International Journal of Dermatology · 2017
    13. Experience with Oral Tofacitinib in 8 Adolescent Patients with Alopecia Universalis Journal of the American Academy of Dermatology · 2017
    14. Alopecia Universalis Unresponsive to Treatment with Tofacitinib: Report of a Case with a Brief Review of the Literature Dermatology online journal · 2017
    15. Excellent Response to Tofacitinib Treatment in a Patient with Alopecia Universalis Acta dermatovenerologica Alpina, Pannonica et Adriatica (Tiskana izd.) · 2017
    16. Tofacitinib for the Treatment of Alopecia Areata and Variants in Adolescents Journal of the American Academy of Dermatology · 2016
    17. Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients Journal of The American Academy of Dermatology · 2016
    18. Remarkable Improvement of Nail Changes in Alopecia Areata Universalis with 10 Months of Treatment with Tofacitinib: A Case Report Case Reports in Dermatology · 2016
    19. Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata JCI insight · 2016
    20. Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata JCI insight · 2016
    21. Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not Plaque Psoriasis with Tofacitinib in a Young Woman Acta dermato-venereologica · 2016
    22. Efficacy of Tofacitinib in Treatment of Alopecia Universalis in Two Patients Journal of the European Academy of Dermatology and Venereology · 2016
    23. Familial Aggregation of Alopecia Areata Journal of the American Academy of Dermatology · 2016
    24. Treatment of an Alopecia Areata Patient with Tofacitinib Results in Regrowth of Hair and Changes in Serum and Skin Biomarkers Experimental Dermatology · 2016
    25. Topical Ruxolitinib for the Treatment of Alopecia Universalis JAMA dermatology · 2015
    26. Tofacitinib Citrate for the Treatment of Nail Dystrophy Associated with Alopecia Universalis JAMA Dermatology · 2015
    27. Pharmacologic Inhibition of JAK-STAT Signaling Promotes Hair Growth Science Advances · 2015
    28. Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib EBioMedicine · 2015
    29. The Autoimmune Basis of Alopecia Areata: A Comprehensive Review Autoimmunity reviews · 2014
    30. Inhibiting Janus Kinases to Treat Alopecia Areata Nature medicine · 2014
    31. Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition Nature medicine · 2014
    32. Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis Journal of Investigative Dermatology · 2014
    33. The Role of Hair Follicle Immune Privilege Collapse in Alopecia Areata: Status and Perspectives Journal of Investigative Dermatology Symposium Proceedings · 2013
    34. Dihydrotestosterone-Inducible IL-6 Inhibits Elongation of Human Hair Shafts by Suppressing Matrix Cell Proliferation and Promotes Regression of Hair Follicles in Mice Journal of Investigative Dermatology · 2011
    35. Genome-Wide Association Study in Alopecia Areata Implicates Both Innate and Adaptive Immunity Nature · 2010
    36. Maintenance of Hair Follicle Immune Privilege Is Linked to Prevention of NK Cell Attack Journal of Investigative Dermatology · 2007
    37. Genomewide Scan for Linkage Reveals Evidence of Several Susceptibility Loci for Alopecia Areata The American Journal of Human Genetics · 2007
    38. Histopathology of Non-Scarring Alopecia Journal of Cutaneous Pathology · 1995
    39. Interleukin 6: Insights Into Its Function in Skin by Overexpression in Transgenic Mice Proceedings of the National Academy of Sciences · 1992

    Related research 4

    1. Tofacitinib Treatment in Patients With Active COVID-19 Infection Curēus · 2021
    2. Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A Promising Therapy for the Treatment of Alopecia Areata: A Case Report of Six Patients International Journal of Trichology · 2018
    3. Brazilian Experience of Treating Alopecia Universalis with Novel Antirheumatic Therapy Tofacitinib: A Case Series Rheumatology and Therapy · 2017
    4. Excellent Response to Tofacitinib Treatment in a Patient with Alopecia Universalis Acta dermatovenerologica Alpina, Pannonica et Adriatica (Tiskana izd.) · 2017